CDK9-IN-2 is a special CDK9 inhibitor extracted from patent WO/2012131594A1 (compound CDKI(8)) and has an IC50 of 5 nM and 7 nM in A2058 skin cell line (72 hours) and H929 multiple myeloma cell line (72 hours), respectively.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
2 mg | In stock | $ 188 | |
4 mg | In stock | $ 357 | |
8 mg | In stock | $ 446 | |
20 mg | In stock | $ 908 | |
40 mg | In stock | $ 1443 |
Description | CDK9-IN-2 is a special CDK9 inhibitor extracted from patent WO/2012131594A1 (compound CDKI(8)) and has an IC50 of 5 nM and 7 nM in A2058 skin cell line (72 hours) and H929 multiple myeloma cell line (72 hours), respectively. |
Targets&IC50 | CDK9:5 nM, H929 multiple myeloma cell line: |
In vitro | CDK9-IN-2 (200 nM) reduces the expression of MEPCE indicating that MEPCE is a pharmacodynamic marker for any CDK9 inhibitor. The expression of MCL1 protein is reduced 2 hours after treatment, and it is further reduced after 16-hour exposure to CDK9-IN-2 (500 nM). |
CAS No. | 1263369-28-3 |
Chemical Formula | C23H25ClFN5 |
Molecular Weight | 425.94 |
Solubility | DMSO: 50 mg/mL (117.39 mM), Need ultrasonic |
Storage | Powder: -20°C for 2 years In solvent: -80°C for 1 year |
bottom